未来针对年龄相关性黄斑变性的抗血管生成方法。

Antiangiogenic approaches to age-related macular degeneration in the future.

作者信息

Do Diana V

机构信息

The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.

出版信息

Ophthalmology. 2009 Oct;116(10 Suppl):S24-6. doi: 10.1016/j.ophtha.2009.06.049.

DOI:10.1016/j.ophtha.2009.06.049

PMID:19800536

Abstract

Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD.

摘要

新生血管性年龄相关性黄斑变性（AMD）是一种复杂的疾病，可能涉及多种促成脉络膜新生血管（CNV）形成的血管生成因子。尽管雷珠单抗抑制血管内皮生长因子已在新生血管性AMD治疗中显示出疗效和安全性，但目前正在研究针对在CNV形成中起作用的不同机制的新型治疗方法。这些临床试验的数据将增加我们对AMD发病机制的了解，并可能为改善AMD患者的视力和生活质量的治疗手段增添新内容。